Compare KMB & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMB | IQV |
|---|---|---|
| Founded | 1910 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Containers/Packaging | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5B | 43.1B |
| IPO Year | 1994 | 2013 |
| Metric | KMB | IQV |
|---|---|---|
| Price | $98.32 | $269.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 16 |
| Target Price | $113.54 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 4.1M | 1.3M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.33% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | ★ 3.03 | 1.61 |
| Revenue | ★ $16,447,000,000.00 | $9,739,000,000.00 |
| Revenue This Year | $3.83 | $6.77 |
| Revenue Next Year | $3.61 | $5.89 |
| P/E Ratio | ★ $32.41 | $167.35 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $92.42 | $154.50 |
| 52 Week High | $125.32 | $273.88 |
| Indicator | KMB | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 30.25 | 67.52 |
| Support Level | $97.28 | $222.95 |
| Resistance Level | $100.65 | $271.80 |
| Average True Range (ATR) | 1.99 | 6.23 |
| MACD | -1.01 | -0.83 |
| Stochastic Oscillator | 8.17 | 81.80 |
With more than half of its sales from personal care and another third from consumer tissue products, Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates in the professional segment, partnering with businesses to provide workplace safety and sanitation solutions. Kimberly-Clark generates just over half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America. It is slated to add Kenvue's consumer health portfolio to its mix in the second half of calendar year 2026.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.